Alnylam Pharmaceuticals (ALNY) PT Raised to $138.00 at Cantor Fitzgerald

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by stock analysts at Cantor Fitzgerald from $135.00 to $138.00 in a research report issued on Monday, BenzingaRatingsTable reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 55.83% from the company’s current price.

A number of other brokerages also recently issued reports on ALNY. ValuEngine raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 1st. Svb Leerink upped their price target on Alnylam Pharmaceuticals from $65.00 to $70.00 and gave the stock a “market perform” rating in a research note on Tuesday, April 9th. BMO Capital Markets upped their price target on Alnylam Pharmaceuticals from $106.00 to $119.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 9th. Chardan Capital reissued a “buy” rating and set a $150.00 price objective on shares of Alnylam Pharmaceuticals in a report on Tuesday, April 9th. Finally, Zacks Investment Research lowered Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the company. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average target price of $128.39.

Shares of ALNY opened at $88.56 on Monday. The stock has a market cap of $9.55 billion, a price-to-earnings ratio of -11.70 and a beta of 2.61. Alnylam Pharmaceuticals has a 12 month low of $60.27 and a 12 month high of $124.21. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.56 and a current ratio of 6.69.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 7th. The biopharmaceutical company reported ($2.09) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.27) by $0.18. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $18.03 million. Alnylam Pharmaceuticals had a negative return on equity of 50.82% and a negative net margin of 1,016.58%. The business’s quarterly revenue was down 44.6% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.20) EPS. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post -8.68 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Panagora Asset Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 31.4% during the third quarter. Panagora Asset Management Inc. now owns 4,094 shares of the biopharmaceutical company’s stock worth $358,000 after acquiring an additional 979 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Alnylam Pharmaceuticals by 768.5% during the third quarter. Tower Research Capital LLC TRC now owns 1,294 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 1,145 shares in the last quarter. Dynamic Technology Lab Private Ltd lifted its position in shares of Alnylam Pharmaceuticals by 55.2% during the third quarter. Dynamic Technology Lab Private Ltd now owns 3,724 shares of the biopharmaceutical company’s stock worth $326,000 after acquiring an additional 1,324 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Alnylam Pharmaceuticals by 6,519.0% during the third quarter. The Manufacturers Life Insurance Company now owns 213,065 shares of the biopharmaceutical company’s stock worth $18,648,000 after acquiring an additional 209,846 shares in the last quarter. Finally, Pacer Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $231,000. 86.88% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Further Reading: Treasury Bonds

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit